U.S. Biotech Firms Collectively "Go Silent" to Fend Off Chinese Competitors
nashnova research
The US biotech industry is abandoning decades of academic openness for information lockdown, driven by Chinese competitors who run clinical trials three times faster at half the cost — a "lights-off" movement that could reshape global drug-development norms.
What exactly are they locking down?
Multiple US biotech firms now follow an unwritten rule: no disclosure of early-stage research, no discussion of unpublished data.
Strand Therapeutics founder Jacob Becraft deliberately delays patent filings to extend the secrecy window — and restricts IP information even from investors.
Curie.Bio co-founder Alexis Borisy tells scientists to "turn off the lights" — no papers, no conference posters, no attendance at all.
This means → the entire industry is shifting from "publish first" to "protect first," overturning a default that held for decades.
Why are Chinese rivals so feared?
Industry lobby group BIO says Chinese firms complete clinical trials three times faster than US counterparts, at half the cost.
Borisy describes a specific mechanism: Chinese institutions have deployed AI agents that scan every conference presentation and every patent filing in real time — any information, once public, is immediately tracked.
In plain terms = a discovery that took a US company ten years to produce can trigger a Chinese clinical trial within months — without starting from scratch.
How wide is the gap in the data?
A JAMA paper tracks the shift: in 2015, the US held 48% of global early-stage drug development and China held 8%; by 2024, the US fell to 37% and China rose to 32%.
Roughly 30% to 35% of innovative drugs currently in development originate from China.
Third Rock Ventures partner Dr. Steven Paul states plainly: "I predict they will surpass us in biotech in the not-too-distant future."
This reflects a systemic expansion across China's entire R&D pipeline — not a single breakthrough.
Is this still just commercial competition?
The Emerging Biotechnology National Security Commission — a US congressional advisory body — warns that if China controls access to a critical drug, such as a cancer treatment, it could use that access as political leverage.
In plain terms = the same playbook as rare-earth export controls during trade disputes — if only China can make a key cancer drug, the bargaining table looks very different.
The Chinese Communist Party ranks biotech alongside AI as a top-priority industry; its five-year plan calls for producing at least 25% of the world's "first-in-class" innovative drugs within five years.
What is the structural weakness on the US side?
Investor Cyriac Roeding and the national-security commission both note that small US biotech firms depend heavily on private investors and are exposed to capital-cycle swings across drug-development timelines exceeding ten years.
The commission recommends an "industry-led, government-partnered" public-private mechanism.
This means → the real test is not just whether to go dark — it is whether firms can lock down information and still attract funding. Academic secrecy makes it harder for investors to evaluate a project's worth; the two goals are inherently in tension.
市场有风险,内容仅供研究参考,不构成投资建议。
